Company Product Description Indication Status Date
Cytodyn Inc., of Vancouver, Wash. Leronlimab (PRO-140) CCR5 antagonist COVID-19 Filed modified IND and protocol for phase II trial for patients who experience respiratory complications as result of contracting COVID-19 3/16/20
Zai Lab Ltd., of Shanghai Zejula (niraparib) PARP inhibitor Epithelial ovarian, fallopian tube or primary peritoneal cancer China’s NMPA accepted the supplemental NDA for use as maintenance treatment of adults with advanced disease who are in complete or partial response to first-line platinum-based chemotherapy 3/16/20

Notes

The date indicated refers to the BioWorld Regulatory actions table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

No Comments